U.S. Markets open in 6 hrs 8 mins
  • S&P Futures

    4,577.75
    +2.00 (+0.04%)
     
  • Dow Futures

    34,685.00
    +63.00 (+0.18%)
     
  • Nasdaq Futures

    15,970.75
    -17.75 (-0.11%)
     
  • Russell 2000 Futures

    2,205.70
    +0.50 (+0.02%)
     
  • Crude Oil

    68.08
    +1.58 (+2.38%)
     
  • Gold

    1,768.80
    +6.10 (+0.35%)
     
  • Silver

    22.31
    -0.01 (-0.03%)
     
  • EUR/USD

    1.1301
    -0.0005 (-0.0452%)
     
  • 10-Yr Bond

    1.4480
    0.0000 (0.00%)
     
  • Vix

    27.95
    -3.17 (-10.19%)
     
  • GBP/USD

    1.3277
    -0.0025 (-0.1885%)
     
  • USD/JPY

    113.4140
    +0.2050 (+0.1811%)
     
  • BTC-USD

    56,750.08
    -173.12 (-0.30%)
     
  • CMC Crypto 200

    1,447.99
    +9.11 (+0.63%)
     
  • FTSE 100

    7,185.13
    +55.92 (+0.78%)
     
  • Nikkei 225

    28,029.57
    +276.20 (+1.00%)
     

Antibe Therapeutics to Present at Canaccord Genuity 41st Annual Growth Conference

  • Oops!
    Something went wrong.
    Please try again later.
·1 min read
In this article:
  • Oops!
    Something went wrong.
    Please try again later.

TORONTO, August 09, 2021--(BUSINESS WIRE)--Antibe Therapeutics Inc. (TSX: ATE, OTCQX: ATBPF), a clinical stage company leveraging its hydrogen sulfide platform to develop next-generation safer therapies for a wide range of inflammatory conditions, today announced its participation in the Canaccord Genuity 41st Annual Growth Conference being held virtually on August 10 - 12. Dan Legault, Antibe’s CEO, and Dr. Joseph Stauffer, Chief Medical Officer, will deliver the Company’s presentation:

Date: Thursday, August 12, 2021
Time: 9:00 am (Eastern Time)

A link to the webcast of the presentation will be available on the News and Events section of the Company’s website at antibethera.com. Following the presentation, a replay of the webcast will be available on the website for 90 days.

About Antibe Therapeutics Inc.

Antibe is leveraging its proprietary hydrogen sulfide platform to develop next-generation safer therapies to address inflammation arising from a wide range of medical conditions. The Company’s current pipeline includes three assets that seek to overcome the gastrointestinal ("GI") ulcers and bleeding associated with nonsteroidal anti-inflammatory drugs ("NSAIDs"). Antibe’s lead drug, otenaproxesul, is in clinical development for the treatment of osteoarthritis pain. Additional assets include a safer alternative to opioids for peri-operative pain, and a GI-sparing alternative to low-dose aspirin. The Company’s next target is inflammatory bowel disease ("IBD"), a condition long in need of safer, more effective therapies. Learn more at antibethera.com.

View source version on businesswire.com: https://www.businesswire.com/news/home/20210809005190/en/

Contacts

Antibe Therapeutics Inc.
Christina Cameron
VP Investor Relations
+1 416-577-1443
christina@antibethera.com